A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye (Q37304878)
Jump to navigation
Jump to search
scientific article published on 20 July 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye |
scientific article published on 20 July 2007 |
Statements
1 reference
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye (English)
1 reference
Mario Sznol
1 reference
Judith E Karp
1 reference
Francis J Giles
1 reference
Ivana Gojo
1 reference
Lawrence Morris
1 reference
Jacqueline Greer
1 reference
Bonny Johnson
1 reference
Mya Thein
1 reference
Jennifer Low
1 reference
20 July 2007
1 reference
1 reference
71-77
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference